MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehae938

Медицинская библиотека · European heart journal · 2025

Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.

Böhm Michael, Butler Javed, Coats Andrew, Lauder Lucas, Mahfoud Felix, Filippatos Gerasimos, Ferreira João Pedro, Pocock Stuart J, Brueckmann Martina, Hauske Sibylle J, Schueler Elke, Wanner Christoph, Verma Subodh, Zannad Faiez, Packer Milton, Anker Stefan D

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.

METHODS

A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.

RESULTS

Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.

CONCLUSIONS

In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.

Для цитирования: Böhm Michael, Butler Javed, Coats Andrew, Lauder Lucas, Mahfoud Felix, Filippatos Gerasimos, Ferreira João Pedro, Pocock Stuart J, Brueckmann Martina, Hauske Sibylle J, Schueler Elke, Wanner Christoph, Verma Subodh, Zannad Faiez, Packer Milton, Anker Stefan D. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.. European heart journal. 2025. DOI: 10.1093/eurheartj/ehae938.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.